Autologous hematopoietic stem cell transplantation (ASCT) outcomes in non-Hodgkin lymphoma (NHL) patients undergoing high dose therapy (HDT) with etoposide, cyclophosphamide and thiotepa (VP/CY/TT) versus cyclophosphamide, carmustine and etoposide (CBV)

被引：0
|
作者：
Veltri, L. W. [1 ]
Shah, N. [1 ]
Cumpston, A. [1 ]
Zhang, J. [1 ]
Wen, S. [1 ]
Watkins, K. [1 ]
Leadmon, S. [1 ]
Craig, M. [1 ]
Hamadani, M. [2 ]
Kanate, A. S. [1 ]
机构：
[1] W Virginia Univ, Hematol Oncol, Morgantown, WV 26506 USA
[2] Med Coll Wisconsin, Hematol Oncol, Milwaukee, WI 53226 USA
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P237
引用
收藏
页码：S238 / S238
页数：1
相关论文
共 50 条
  • [41] Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease
    DE Reece
    TJ Nevill
    A Sayegh
    JJ Spinelli
    DA Brockington
    MJ Barnett
    H-G Klingemann
    JM Connors
    SH Nantel
    JD Shepherd
    HJ Sutherland
    NJS Voss
    RN Fairey
    SE O’Reilly
    GL Phillips
    Bone Marrow Transplantation, 1999, 23 : 1131 - 1138
  • [42] A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL).
    Nademanee, A
    Molina, A
    Forman, SJ
    Kogut, N
    Yamauchi, D
    An, L
    White, CA
    Raubitschek, A
    BLOOD, 2002, 100 (11) : 182A - 182A
  • [43] Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide
    Dean, Robert M.
    Pohlman, Brad
    Sweetenham, John W.
    Sobecks, Ronald M.
    Kalaycio, Matt E.
    Smith, Stephen D.
    Copelan, Edward A.
    Andresen, Steven
    Rybicki, Lisa A.
    Curtis, Julie
    Bolwell, Brian J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (02) : 226 - 234
  • [44] High dose cyclophosphamide, Carmustine and Etoposide for non-Hodgkin's lymphoma is a safe and effective conditioning regimen for allogeneic progenitor cell transplant.
    Levy, W
    Baretti, M
    Becker, P
    Butler, K
    Emmons, R
    Doyle, P
    Quesenberry, P
    Stewart, M
    Ballen, K
    BLOOD, 1999, 94 (10) : 383B - 383B
  • [45] Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL)
    Jae-Cheol Jo
    Jin Seok Kim
    Je-Hwan Lee
    Jung-Hee Lee
    Sung-Nam Lim
    Sang Min Lee
    Sung-Soo Yoon
    In-Ho Kim
    Sung Hwa Bae
    Yoo Jin Lee
    Yunsuk Choi
    Won-Sik Lee
    Bone Marrow Transplantation, 2020, 55 : 1466 - 1468
  • [46] Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL)
    Jo, Jae-Cheol
    Kim, Jin Seok
    Lee, Je-Hwan
    Lee, Jung-Hee
    Lim, Sung-Nam
    Lee, Sang Min
    Yoon, Sung-Soo
    Kim, In-Ho
    Bae, Sung Hwa
    Lee, Yoo Jin
    Choi, Yunsuk
    Lee, Won-Sik
    BONE MARROW TRANSPLANTATION, 2020, 55 (07) : 1466 - 1468
  • [47] Busulfan, etoposide, cytarabine and melphalan (BUEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-hodgkin lymphoma (NHL)
    Jo, Jae-Cheol
    Kim, Jin-Seok
    Lee, Je-Hwan
    Lee, Jung-Hee
    Im, Seong Nam
    Lee, Won-Sik
    Lee, Sang-Min
    Yoon, Sung-Soo
    Kim, In-Ho
    Choi, Yun Suk
    Bae, Seong Hwa
    BONE MARROW TRANSPLANTATION, 2019, 54 : 209 - 210
  • [48] Tandem high dose chemotherapy for non-Hodgkin's lymphoma and Hodgkin's disease utilizing cyclophosphamide, etoposide and carboplatin followed by melphalan and carboplatin with autologous stem cell transplantation.
    Andrey, J
    Burian, C
    McMillan, R
    Miller, WE
    Meisenberg, B
    Mason, JR
    BLOOD, 2000, 96 (11) : 367B - 367B
  • [49] HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE AND BCNU WITH NON-CRYOPRESERVED AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR POOR PROGNOSIS HODGKIN'S LYMPHOMA
    Brahimi, M.
    Yafour, N.
    Osmani, S.
    Attaf, F.
    Tadj, H.
    Arabi, A.
    Soltan, B. Enta
    Berredouane, H.
    Benzineb, B.
    Bey, M.
    Bahlat, N.
    Bekadja, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 655 - 656
  • [50] Long-term outcomes of high-dose etoposide and melphalan chemotherapy and autologous stem cell transplantation for non-Hodgkin lymphoma
    Kuruvilla, J.
    Zadeh, S.
    Franke, N.
    Nagy, T.
    Saragosa, R.
    Crump, M.
    Keating, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S148 - S149
12345